Eagle Asset Management Inc. Cuts Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Eagle Asset Management Inc. lessened its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 29.3% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 217,338 shares of the medical equipment provider's stock after selling 90,246 shares during the period. Eagle Asset Management Inc. owned about 0.31% of Lantheus worth $23,853,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of LNTH. Farallon Capital Management LLC grew its stake in shares of Lantheus by 595.3% during the first quarter. Farallon Capital Management LLC now owns 1,483,227 shares of the medical equipment provider's stock worth $92,316,000 after purchasing an additional 1,269,900 shares in the last quarter. Swedbank AB purchased a new position in shares of Lantheus in the 1st quarter valued at about $26,346,000. Vanguard Group Inc. raised its position in shares of Lantheus by 5.6% during the 1st quarter. Vanguard Group Inc. now owns 7,362,969 shares of the medical equipment provider's stock worth $458,271,000 after acquiring an additional 389,828 shares in the last quarter. Point72 Asset Management L.P. purchased a new stake in Lantheus during the second quarter worth approximately $26,794,000. Finally, Massachusetts Financial Services Co. MA acquired a new position in Lantheus in the third quarter valued at approximately $25,955,000. 99.06% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts have recently weighed in on LNTH shares. Truist Financial restated a "buy" rating and set a $120.00 price objective (down previously from $135.00) on shares of Lantheus in a research report on Friday, November 8th. Redburn Atlantic began coverage on shares of Lantheus in a research report on Tuesday, September 3rd. They issued a "buy" rating and a $175.00 price target for the company. JMP Securities dropped their price objective on Lantheus from $125.00 to $112.00 and set a "market outperform" rating on the stock in a report on Thursday, November 7th. Finally, StockNews.com downgraded Lantheus from a "buy" rating to a "hold" rating in a report on Thursday. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $122.50.

Lantheus Price Performance

Shares of NASDAQ:LNTH traded up $3.20 during trading on Friday, reaching $90.52. The company had a trading volume of 2,014,988 shares, compared to its average volume of 1,546,289. The stock's fifty day moving average price is $103.43 and its 200 day moving average price is $96.53. Lantheus Holdings, Inc. has a fifty-two week low of $50.20 and a fifty-two week high of $126.89. The firm has a market capitalization of $6.29 billion, a price-to-earnings ratio of 15.06 and a beta of 0.51.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.